Skip to main content

Table 2 Mechanism and drug resistance of m6A regulatory factor in related tumors

From: Recent advances of m6A methylation modification in esophageal squamous cell carcinoma

Related tumors m6A regulator Roles Study model Mechanism Resistance Ref.
Breast cancer METTL3 Oncogene In vitro: MCF-7 METTL3, hepatitis B virus X protein binding protein (HBXIP) and miRNA let-7 g form a positive feedback loop Tamoxifen [41]
ALKBH5 Oncogene In vivo: mice Demethylation of NANOG and increase of mRNA level [42]
Ovarian cancer YTHDF1 Oncogene In vitro: SKOV3, A2780 TRIM29 may be used as an oncogene Cisplatin [43]
FTO/ALKBH5 Oncogene In vitro: PEO1 Up-regulation of Wnt/ β-catenin pathway by stabilizing FZD1 Olaparib [44]
Cervical cancer FTO Oncogene In vitro: SiHa Regulation of β-catenin/ERCC1 axis [45]
Acute myeloid leukemia (AML) METTL3 Oncogene In vitro: MOLM13, THP-1, MV4-11, NOMO-1, HL-60, EOL-1, KG-1, RN2c, HEL, JURKA T, LOUCY, K562 Regulating the expression of c-Myc, Bcl-2 and PTEN [46]
METTL14 Oncogene In vivo: human Enhanced self-renewal of hematopoietic stem cells and inhibition of bone marrow cell differentiation through SPI1-METTL14-MYB/MYC axis [47]
WTAP Oncogene In vitro: K562,HL-60,OCI-AML3,Ba/F3 Regulating WT1 pathway to promote cell proliferation [48]
Glioblastomas (GBMs) METTL3 Oncogene In vivo: human Inhibition of tumorigenesis and self-renewal / proliferation of MSCs Y- Irradiation [49]
METTL14 Suppressor In vivo: human It is possible to target ADAM19 to inhibit tumorigenesis and self-renewal / proliferation of glioma stem-like cells (GSCs) [50]
FTO Oncogene In vivo: human The inhibitory effect of drugs on FTO can inhibit the formation of m6A demethylation gene in glioblastoma [50]
ALKBH5 Oncogene In vivo: mice Demethylated FOXM1 promotes tumorigenicity of GSC [51]
Non-small cell lung cancer
METTL3 Oncogene In vitro: A549, H1299, Calu6,H520,95-D, PC9,HCC827 SUMO promotes tumor growth of lysine residues K177, K211, K212 and K215 in NSCLC Cisplatin/
[52, 53]
WTAP Oncogene In vitro: H1299, A549, EBC-1, HCC827,CALU-3, H661,H596, H358, H460,H1650, H1975, H1395,H292 Down-regulation of c-MET expression Crizotinib [54]
YTHDF1 Suppressor In vitro: HEK-293T, H1975, A549, NCI-H838, H1299, NCI-H1650,GLC-82, SPC-A1 regulating the translational efficiency of CDK2, CDK4, and cyclin D1 Cisplatin [55]
Hepatocellular cance METTL3 Oncogene In vitro: HepG2,Huh-7,MHCC97L, HepG-2,Hepa1-6, HEK-293T,WRL68, HUVEC,SMMC-7721, Bel7402,HepG-2, WRL68, HEK-293T Reduce the stability of SOCS2 mRNA Sorafenib [56, 57]
METTL14 Oncogene In vivo: mice Progress in regulating miR-126 through DGCR8 Sorafenib [58]
YTHDF2 Oncogene In vitro: HepG2,293T MiR-145 regulates m6A level by targeting YTHDF2 mRNA 3-UTR in hepatocellular carcinoma cells [59]
Gastric cancer METTL3 Suppressor In vitro: AGS,HGC-27, MKN-45 mediated this process occurred on the A879 locus of pri-miR-17-92 Everolimus [60]
Colorectal cancer YTHDF1 Oncogene In vitro: SW480,CaCO2, HT29, RKO,DLD-1, KM12SM, HCT-116,LoVo C-Myc promotes the expression of YTHDF1 and affects the proliferation and chemosensitivity of colorectal cancer Oxaliplatin/ 5-Fu [61]
Pancreatic cancer METTL3 Oncogene In vitro: MIA PaCa-2 METTL3 is associated with mitogen-activated protein kinase cascades, ubiquitin-dependent process and RNA splicing and regulation of cellular process Cisplatin/
Fu /